Dermatovenerologiya va estetik tibbiyot

prOper mONItOrING Of the uSe Of ImIQuImOd fOr the treAtmeNt Of bcc, 
actinic keratosis
SVYATENKO TETYANA
1
, PROKHACH ANDRII
2
«Dnipropetrovsk Medical Academy«Ministry of Health»
1
 
«Clinical Oncology Center» DOS, Ukraine
2
modern Dermatooncology has a number of new 
techniques for the treatment of preсanсrosis, basal 
cell carcinoma of the skin (bCC), among them — the 
use of local immune response modifiers. Immediately 
skin tumor immunotherapy is a promising method 
of treatment. Previously it used α-interferon for 
the palliative treatment of common bCC. Today, 
a wide spread of receive immunomodulators 
which have been applied in Dermatooncology.
Imidazohinalins — a new group of drugs nedovno 
entered into clinical practice as anti-tumor and anti-
viral immune modulators. Imiquimod (guanosine 

---

106
Дерматовенерология и эстетическая меДицина № 3/2015
derivative) is a specific receptor agonist Tlr7. 
There are indications of a direct effect of imiquimod 
both adenosine receptors and other molecules that 
regulate the synthesis of cyclic 3-amP and 5. We 
observed 35 patients treated with imiquimod as 
a therapy for actinic keratosis, bCC. Tolerability 
satisfactory, however, in 9 (25,7 %) cases occurred 
hyperergic reaction that fits into the description of the 
side effects of the drug. The therapeutic effect was 
observed in 35 patients (100 %).We observed that the 
inflammatory reaction that occurs during treatment 
with the drug, it is correlated with the therapeutic 
effect, but in turn, lengthens the treatment of 8–10 
weeks, due to the forced interruption. This problem 
has been observed in 9 patients (25,7 %).
Conclusions:
1) the use of imiquimod in the initial stages of 
the bCC, actinic keratosis with a skin lesion to avoid 
aesthetic defects associated with surgery;
2) inflammatory response extends treatment;
3) individual selection of dosage and frequency of 
use;
4) expanding opportunities for a choice of tactics 
and treatment of bCC, actinic keratosis;
5) improves pharmacoeconomics.